摘要
目的探究乳腺癌不同分子分型和临床病理特征对预后的影响。方法以本院2014年2月~2017年5月收治的200例乳腺癌患者为研究对象,所有患者均经PR(孕激素)、ER(雌激素)、HER-2(人表皮生长因子受体-2)、Ki-67以及CK5/6检查进行分型,主要分为基底样型、HER-2过表达型、LuminalB型、LuminalA型,分析不同分子分型乳腺癌患者的临床病理特征以及其预后情况。结果不同分子分型乳腺癌患者,其年龄、病理类型、临床分期、腋淋巴结分期、肿瘤大小等病理参数以及局部复发率、远处转移率、两年内生存率相比,均存在统计学差异(P <0.05)。结论不同分子分型乳腺癌患者的临床病理特征以及预后之间存在一定差异。
Objective To explore the effect of different molecular types and clinicopathological features of breast cancer on prognosis. Methods A total of 200 patients with breast cancer admitted to Xiangcheng Hospital of Traditional Chinese Medicine from February 2014 to May 2017 were classified by PR (progesterone), ER (estrogen), HER-2 (human epidermal growth factor receptor-2), Ki-67 and CK5/6. The patients were divided into basal type, HER-2 overexpression type and Luminal B type. Luminal A was used to analyze the clinicopathological characteristics and prognosis of breast cancer patients with different molecular types. Results There were significant differences in age, pathological type, clinical stage, Axillary lymph node staging, tumor size, local recurrence rate, distant metastasis rate, and 2 year survival rate in different molecular types of breast cancer patients (P < 0.05). Conclusion There are some differences in clinicopathological features and prognosis between breast cancer patients with different molecular typing.
作者
郝增山
HAO Zeng-shan(Department of pathology, xiangcheng hospital of traditional Chinese medicine, Henan province,Xiangcheng, Heana, 466200, China)
出处
《临床研究》
2019年第7期40-41,共2页
Clinical Research
关键词
乳腺癌
分子分型
临床病理特征
预后
breast cancer
molecular type
clinicopathological features
prognosis
